Azilsartan (EDARBI): A New Angiotensin Receptor Blocker (ARB) for Hypertension

Approved by the FDA for Marketing in the USA

Randa Hilal-Dandan


AccessMedicine from McGraw-Hill 

In This Article

Adverse Effects and Contraindications

Azilsartan is well-tolerated; adverse effects are similar to those of other ARBs (e.g., valsartan and olmesartan) and placebo. The most common adverse effect is diarrhea (2%). Less commonly reported adverse effects include orthostatic hypotension, nausea, fatigue, dizziness, muscle spasm, and cough.

Small but reversible increases in serum creatinine levels were detected in some patients on 80 mg azilsartan medoxomil.[2,6] These increases in serum creatinine levels were observed mostly in patients >75 years of age with moderate to severe renal impairment. Low hemoglobin and RBC counts were detected in <0.4% of drug-treated patients compared to none in the placebo group. There was no evidence of QT/QTc prolongation at the highest dose of 320 mg azilsartan medoxomil.[2]